Summary of Study ST001795

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001139. The data can be accessed directly via it's Project DOI: 10.21228/M8GH59 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001795
Study TitleChanges in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib (part I)
Study TypeUntargeted lipidomics analysis
Study SummaryUntargeted lipid profiling of mesenteric mice lymph from mice fed with CHOW, HFD and HFD supplemented with COx-2 inhibitor drug Celecoxib. It is proposed that Celecoxib can protect from deleterious morphological changes in lymphatic system caused by obesity/HFD.
Institute
Monash Institute of Pharmaceutical Sciences
DepartmentDrug Delivery, Disposition and Dynamics
LaboratoryTrevaskis Lab, Creek Lab
Last NameAnderson
First NameDovile
Address6 Anderson
Emaildovile.anderson@gmail.com
Phone8671141
Submit Date2021-05-12
Num Groups3
Total Subjects26
Num Males26
PublicationsManuscript NATMETAB-A20022406A Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential novel treatment target in obesity
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2021-06-02
Release Version1
Dovile Anderson Dovile Anderson
https://dx.doi.org/10.21228/M8GH59
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001139
Project DOI:doi: 10.21228/M8GH59
Project Title:Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib
Project Type:Untargeted lipidomics
Project Summary:Untargeted lipidomic profiling of mice mesenteric lymph upon HFD diet and HFD supplemented with COX-2 inhibitor drug Celecoxib. It is proposed that Celecoxib can rescue from negative morphological changes induced by obesity/HFD diet in lymphatic system.
Institute:Monash Institute of Pharmaceutical Sciences
Department:Drug Delivery, Disposition and Dynamics
Laboratory:Trevaskis Lab, Creek Lab
Last Name:Anderson
First Name:Dovile
Address:399 Royal Pd
Email:dovile.anderson@monash.edu
Phone:+61448671141
Funding Source:Department of Health | National Health and Medical Research Council (NHMRC) - 1100036 [Trevaskis]
Project Comments:This lipidomics project is part of a larger obesity/lymph research as described in the manuscript
Publications:Manuscript NATMETAB-A20022406A Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential novel treatment target in obesity
Contributors:Dr Enyuan Cao , Matthew Watt , Cameron Nowell , Dr Tim Quach , Jamie Simpson , Ms Violena Ferreira , Sonya Argawal , Hannah Chu , Anubhav Srivastava , Dr Dovile Anderson , Gracia Gracia , Alina Lam , Gabriela Segal , Jiwon Hong , Dr Luojuan Hu , Kian Lium Phang , Alistair Escott , Professor John Windsor , Anthony Phillips , Darren Creek , Professor Natasha Harvey , Professor Christopher Porter

Subject:

Subject ID:SU001872
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090
Genotype Strain:C57BL6/J
Age Or Age Range:6-7 weeks
Gender:Male
Animal Housing:temperature-controlled room under specific-pathogen free (SPF) or standard animal housing conditions with free access to food and water
Animal Feed:semi-purified normal chow diet (control fat diet (CFD), 7% w/w fat and 16% total energy from fat; AIN93G, Specialty Feeds Pty Ltd, Australia) or high fat diet (HFD, 36% w/w fat and 59% total energy from fat; SF03-002, Specialty Feeds Pty Ltd, Australia)
Animal Water:ad libitum

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA167157Celecoxib_HFD_3Celecoxib_HFD
SA167158Celecoxib_HFD_9Celecoxib_HFD
SA167159Celecoxib_HFD_2Celecoxib_HFD
SA167160Celecoxib_HFD_5Celecoxib_HFD
SA167161Celecoxib_HFD_4Celecoxib_HFD
SA167162Celecoxib_HFD_8Celecoxib_HFD
SA167163Celecoxib_HFD_1Celecoxib_HFD
SA167164Celecoxib_HFD_7Celecoxib_HFD
SA167165Celecoxib_HFD_6Celecoxib_HFD
SA167149CFD_3CFD
SA167150CFD_2CFD
SA167151CFD_4CFD
SA167152CFD_7CFD
SA167153CFD_8CFD
SA167154CFD_1CFD
SA167155CFD_6CFD
SA167156CFD_5CFD
SA167166HFD_7HFD
SA167167HFD_8HFD
SA167168HFD_9HFD
SA167169HFD_6HFD
SA167170HFD_1HFD
SA167171HFD_2HFD
SA167172HFD_3HFD
SA167173HFD_4HFD
SA167174HFD_5HFD
Showing results 1 to 26 of 26

Collection:

Collection ID:CO001865
Collection Summary:The efferent mesenteric lymphatic duct was cannulated in isoflurane anaesthetised non-fasted mice or rats and lymph fluid was collected for up to 4 h. For the lymphatic drug transport study, lymph was collected in mice that were fasted for 3-4 h. The mesenteric lymph duct cannulation was performed as described previously in rats4 and mice5 and mesenteric lymph fluid was collected continuously for up to 6 h.
Sample Type:Mesenteric lymph
Storage Conditions:-80℃

Treatment:

Treatment ID:TR001885
Treatment Summary:Celecoxib was incorporated into HFD feed at a dose equivalent to ~29 mg/kg/day (based on average food intake). Mice were fed for 15 weeks before the analysis.

Sample Preparation:

Sampleprep ID:SP001878
Sampleprep Summary:For lipidomics analysis, lipid was extracted from mesenteric lymph by chloroform:methanol (1:3). Samples were vortexed for 1 h at 4°C and then centrifuged at 16,000 g for 10 min. Supernatant was carefully transferred to another tube and stored at -80°C until analysis. Before LC-MS analysis, the extract was dried with nitrogen and reconstituted in 20 µl water and 180 µl butanol-methanol (1:1 v/v). The reconstituted extract was vortexed (Vortex mixer, Ratek) for 200 sec with 20 cycles of 5 sec spin and 20 sec vortex. The extract was sonicated in a water bath for 1 hour which was maintained at <20°C by sonicating the samples on ice. The samples were then centrifuged for 10 min at 16,000 g and the supernatant was transferred to LC-MS vials and stored at 4°C prior to analysis.
Processing Storage Conditions:4℃
Extract Storage:-80℃

Combined analysis:

Analysis ID AN002915 AN002916
Analysis type MS MS
Chromatography type Reversed phase Reversed phase
Chromatography system Thermo Dionex Ultimate 3000 RS Thermo Dionex Ultimate 3000 RS
Column Sigma Aldrich,Supleco,C8 (100 x 2.1mm,2.7um) Sigma Aldrich,Supleco,C8 (100 x 2.1mm,2.7um)
MS Type ESI ESI
MS instrument type Orbitrap Orbitrap
MS instrument name Thermo Q Exactive Orbitrap Thermo Q Exactive Orbitrap
Ion Mode POSITIVE NEGATIVE
Units height height

Chromatography:

Chromatography ID:CH002159
Chromatography Summary:Lipidomics analysis was performed using reversed phase liquid chromatography and high-resolution mass spectrometry. Samples (10 µl) were injected onto a Dionex Ultimate 3000 UHPLC system (Thermo Scientific, Australia) fitted with an analytical C8 column (100 x 2.1 mm; 2.7 µm, Sigma Aldrich, Australia). Chromatography was performed using solvent A (2 mM formic acid, 8 mM ammonium formate, 40% v/v isopropanol) and solvent B (2 mM formic acid, 8 mM ammonium formate, 98% v/v isopropanol) as mobile phases with a 30 min gradient starting at 0% B and increasing to 35% B from 0 to 8 min, then to 50% B from 8-16 min, then to 80% B from 16-19 min, then finally to 100% B by 23 min. 100% B was maintained for a further 3 min before equilibrating to 0% by 28 min and washing for a further 2 min.
Instrument Name:Thermo Dionex Ultimate 3000 RS
Column Name:Sigma Aldrich,Supleco,C8 (100 x 2.1mm,2.7um)
Column Temperature:40C
Flow Gradient:0 min - 0%B, 8 min - 35%B, 16 min - 50%B, 19 min - 80%B, 23 min 100%B, 26 min - 100%B, 28 min - 0%B
Flow Rate:0.2 ml/min
Injection Temperature:4
Solvent A:40% isopropanol/60% water; 2 mM formic acid; 8 mM ammonium formate,
Solvent B:98% isopropanol/2% water; 2 mM formic acid; 8 mM ammonium formate
Analytical Time:30 min
Oven Temperature:40C
Sample Loop Size:25 uL
Sample Syringe Size:25 uL
Chromatography Type:Reversed phase

MS:

MS ID:MS002707
Analysis ID:AN002915
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Pos and neg data were acquired during the same chromatographic run using polarity switching. Full scan acquisition mode, resolution 140k, AGC target 3e6, max IT 200 ms, mass range 140-2000 m/z, number of scans 1
Ion Mode:POSITIVE
Mass Accuracy:3 ppm
Automatic Gain Control:3e6
Desolvation Gas Flow:34
Interface Voltage:3.5 kV
  
MS ID:MS002708
Analysis ID:AN002916
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Pos and neg data were acquired during the same chromatographic run using polarity switching. Full scan acquisition mode, resolution 140k, AGC target 3e6, max IT 200 ms, mass range 140-2000 m/z, number of scans 1
Ion Mode:NEGATIVE
Mass Accuracy:3 ppm
Automatic Gain Control:3e6
Desolvation Gas Flow:34
Interface Voltage:3.5 kV
  logo